ANDA Suitability Petitions: The Timelines They Are A-Changin'

US suitability petition submissions see an uptick against the backdrop of GDUFA III new goals for the FDA's response to such petitions. The Pink Sheet tracks some of the activity as applicants seek to tap market opportunities without the need for new clinical data.

US FDA enhancing processes for reviewing suitability petitions • Source: Shutterstock

More from Generics

More from Biosimilars & Generics